Jun 09, 2021 8:30am EDT SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections
Jun 02, 2021 7:30am EDT SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections
May 17, 2021 8:30am EDT SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 14, 2021 8:30am EDT SCYNEXIS Secures Term Loan Facility for up to $60 Million with Hercules Capital and Silicon Valley Bank
May 11, 2021 8:30am EDT SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch
Apr 30, 2021 8:00am EDT SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections
Apr 20, 2021 8:00am EDT SCYNEXIS to Present Two Ibrexafungerp (Brexafemmeᵀᴹ) Posters at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting
Mar 29, 2021 8:20am EDT SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Mar 02, 2021 7:30am EST SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
